Other substances

Rupintrivir

A human rhinovirus 3C protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

3
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

Rupintrivir on PubChem

 

Structure image - Rupintrivir

CCOC(=O)/C=C/[C@H](C[C@@H]1CCNC1=O)NC(=O)[C@H](CC2=CC=C(C=C2)F)CC(=O)[C@H](C(C)C)NC(=O)C3=NOC(=C3)C

Supporting references

Link Tested on Impact factor Notes Publication date
Bepridil is potent against SARS-CoV-2 in vitro
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay; Vero E6 cells; A459/ACE2 cells; SARS-CoV-2 live virus 9.41 Feb/17/2021
A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19
Preprint Screening 		human A549-ACE2 cells Jun/23/2020
Discovery of Synergistic and Antagonistic Drug Combinations against SARS-CoV-2 In Vitro
Preprint In silico 		VERO E6 cell cultures

synergistic effect in combination with mefloquine

 Jul/01/2020

AI-suggested references

Link Publication date
Pan-3C Protease Inhibitor Rupintrivir Binds SARS-CoV-2 Main Protease in a Unique Binding Mode
Sep/10/2021
Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2
Apr/12/2021
Export (.csv)